Study of neuroblastoma cell characteristics and treatment outcomes
N2004-05: Neuroblastoma Biology Study
New Approaches to Neuroblastoma Therapy Consortium · NCT01587300
This study is collecting samples from children with high-risk neuroblastoma to learn more about the disease and find better ways to treat it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 31 Days to 99 Years |
| Sex | All |
| Sponsor | New Approaches to Neuroblastoma Therapy Consortium (other) |
| Locations | 17 sites (Los Angeles, California and 16 other locations) |
| Trial ID | NCT01587300 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather and analyze samples of neuroblastoma tissues, blood, and bone marrow from children diagnosed with high-risk neuroblastoma. Researchers will establish a biobank of these samples to facilitate laboratory studies focused on understanding the biology of neuroblastoma and improving treatment strategies. Clinical data, including treatment history and tumor characteristics, will also be collected to enhance the research efforts. The ultimate goal is to improve detection, measurement, and treatment response monitoring for neuroblastoma.
Who should consider this trial
Good fit: Ideal candidates include children over 31 days old diagnosed with high-risk neuroblastoma, including those with refractory or recurrent disease.
Not a fit: Patients with low-risk neuroblastoma or those who do not meet the age and diagnosis criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options and better outcomes for children with neuroblastoma.
How similar studies have performed: Other studies focusing on the biology of neuroblastoma have shown promise in improving treatment strategies, indicating that this approach is supported by prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients must be greater than or 31 days of age. * Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. * All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted. * Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized. Exclusion Criteria: * There are no exclusion criteria on this study.
Where this trial is running
Los Angeles, California and 16 other locations
- Children's Hospital Los Angeles — Los Angeles, California, United States (RECRUITING)
- Lucille Salter Packer Children's Hospital, Stanford University — Palo Alto, California, United States (COMPLETED)
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States (RECRUITING)
- Children Hospital of Colorado — Aurora, Colorado, United States (RECRUITING)
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus — Atlanta, Georgia, United States (RECRUITING)
- University of Chicago, Comer Children's Hospital — Chicago, Illinois, United States (RECRUITING)
- Children's Hospital Boston — Boston, Massachusetts, United States (RECRUITING)
- C.S Mott Children's Hospital — Ann Arbor, Michigan, United States (RECRUITING)
- University of North Carolina — Chapel Hill, North Carolina, United States (COMPLETED)
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (RECRUITING)
- Nationwide Children's Hospital — Columbus, Ohio, United States (RECRUITING)
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (RECRUITING)
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States (NOT_YET_RECRUITING)
- University of Texas Southwestern — Dallas, Texas, United States (NOT_YET_RECRUITING)
- Cook Children's Medical Center - Fort Worth — Fort Worth, Texas, United States (RECRUITING)
- Seattle Children's Hospital — Seattle, Washington, United States (RECRUITING)
- Hospital for Sick Children — Toronto, Ontario, Canada (RECRUITING)
Study contacts
- Study coordinator: Araz Marachelian, MD
- Email: amarachelian@chla.usc.edu
- Phone: 323-361-5687
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neuroblastoma